U.S. Prostate Cancer Treatment Device Market Research Report: By Type (Radiation, Surgery, High-Intensity Focused Ultrasound, Cryotherapy), End User (Hospitals, Specialty Centers) - Industry Analysis and Growth Forecast to 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Type

1.3.2 Market Segmentation by End User

1.3.3 Market Segmentation by State

1.3.4 Analysis Period

1.3.5 Market Data Reporting Unit

1.3.5.1 Value

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Split of Primary Research Information

2.2.2 Breakdown of Primary Research by Industry Participant

2.2.3 Breakdown of Primary Research by company type

2.2.4 Breakdown of Primary Research by Company and Designation

2.3 Baseline Methodology

2.4 Market Size Estimation

2.5 Data Triangulation

2.6 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Type

4.1.1.1 Radiation

4.1.1.1.1 Clinical trials

4.1.1.2 Surgery

4.1.1.2.1 Clinical trials

4.1.1.3 HIFU

4.1.1.3.1 Clinical trials

4.1.1.4 Cryotherapy

4.1.1.4.1 Clinical trials

4.1.1.5 Others

4.1.2 By End User

4.1.2.1 Hospitals

4.1.2.2 Specialty centers

4.1.2.3 Others

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Adoption of robotic prostatectomy

4.2.1.2 Accelerating evolution in radiotherapy techniques

4.2.2 Drivers

4.2.2.1 Technological advancements

4.2.2.2 Increasing prevalence of prostate cancer

4.2.2.3 Rising number of government initiatives

4.2.2.4 Surging geriatric population

4.2.2.5 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Longer approval time for prostate cancer devices

4.2.3.2 Challenges in identifying molecular predictors of response to radiotherapy

4.2.3.3 Impact analysis of drivers on market forecast

4.2.4 Opportunities

4.2.4.1 Positioning devices to improve treatment and patient experience

4.3 COVID-19 Impact on U.S. Prostate Cancer Treatment Devices Market

4.3.1 Supply Side Analysis

4.3.2 Demand Side Analysis

4.4 Porter’s Five Forces Analysis

4.4.1 Bargaining Power of Buyers

4.4.2 Bargaining Power of Suppliers

4.4.3 Intensity of Rivalry

4.4.4 Threat of New Entrants

4.4.5 Threat of Substitutes

4.5 Therapy Comparison

4.5.1 HIFU Therapy

4.5.2 Surgery Vs Radiation Therapy

4.5.3 Cryotherapy

4.6 Average Pricing of Devices

Chapter 5. U.S. Market Size and Forecast

5.1 By Type

5.2 By End User

5.3 By State

Chapter 6. Competitive Landscape

6.1 Product Benchmarking of Key Players

6.2 Strategic Developments of Key Players

6.2.1 Approvals and Product Launch

6.2.2 Mergers and Acquisitions

6.2.3 Other Developments

Chapter 7. Company Profiles

7.1 SonaCare Medical LLC

7.1.1 Business Overview

7.1.2 Product and Service Offerings

7.2 EDAP TMS SA

7.2.1 Business Overview

7.2.2 Product and Service Offerings

7.2.3 Key Financial Summary

7.3 Profound Medical Corporation

7.3.1 Business Overview

7.3.2 Product and Service Offerings

7.3.3 Key Financial Summary

7.4 Eckert & Ziegler AG

7.4.1 Business Overview

7.4.2 Product and Service Offerings

7.4.3 Key Financial Summary

7.5 HealthTronics Inc.

7.5.1 Business Overview

7.5.2 Product and Service Offerings

7.6 Boston Scientific Corporation

7.6.1 Business Overview

7.6.2 Product and Service Offerings

7.6.3 Key Financial Summary

7.7 Elekta AB

7.7.1 Business Overview

7.7.2 Product and Service Offerings

7.7.3 Key Financial Summary

7.8 Accuray Incorporated

7.8.1 Business Overview

7.8.2 Product and Service Offerings

7.8.3 Key Financial Summary

7.9 Varian Medical Systems Inc.

7.9.1 Business Overview

7.9.2 Product and Service Offerings

7.9.3 Key Financial Summary

7.10 Becton, Dickinson and Company

7.10.1 Business Overview

7.10.2 Product and Service Offerings

7.10.3 Key Financial Summary

7.11 Intuitive Surgical Inc.

7.11.1 Business Overview

7.11.2 Product and Service Offerings

7.11.3 Key Financial Summary

7.12 ViewRay Inc.

7.12.1 Business Overview

7.12.2 Product and Service Offerings

7.12.3 Key Financial Summary

7.13 Provision Healthcare

7.13.1 Business Overview

7.13.2 Product and Service Offerings

7.14 Isoray Inc.

7.14.1 Business Overview

7.14.2 Product and Service Offerings

7.14.3 Key Financial Summary

7.15 Theragenics Corporation

7.15.1 Business Overview

7.15.2 Product and Service Offerings

Chapter 8. Appendix

8.1 Abbreviations

8.2 Sources and References

8.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 RADIATION - CLINICAL TRIAL - 1

TABLE 3 RADIATION - CLINICAL TRIAL - 2

TABLE 4 RADIATION - CLINICAL TRIAL - 3

TABLE 5 RADIATION - CLINICAL TRIAL - 4

TABLE 6 RADIATION - CLINICAL TRIAL - 5

TABLE 7 RADIATION - CLINICAL TRIAL - 6

TABLE 8 RADIATION - CLINICAL TRIAL - 7

TABLE 9 RADIATION - CLINICAL TRIAL - 8

TABLE 10 SURGERY - CLINICAL TRIAL - 1

TABLE 11 SURGERY - CLINICAL TRIAL - 2

TABLE 12 SURGERY - CLINICAL TRIAL - 3

TABLE 13 SURGERY - CLINICAL TRIAL - 4

TABLE 14 SURGERY - CLINICAL TRIAL - 5

TABLE 15 SURGERY - CLINICAL TRIAL - 6

TABLE 16 SURGERY - CLINICAL TRIAL - 7

TABLE 17 HIFU - CLINICAL TRIAL - 1

TABLE 18 HIFU - CLINICAL TRIAL - 2

TABLE 19 HIFU - CLINICAL TRIAL - 3

TABLE 20 HIFU - CLINICAL TRIAL - 4

TABLE 21 HIFU - CLINICAL TRIAL - 5

TABLE 22 HIFU - CLINICAL TRIAL - 6

TABLE 23 HIFU - CLINICAL TRIAL - 7

TABLE 24 CRYOTHERAPY - CLINICAL TRIAL - 1

TABLE 25 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 26 RESTRAINT FOR THE MARKET: IMPACT ANALYSIS

TABLE 27 HIFU – SONABLATE VS AMBLATHERM (SYSTEM SPECIFICATION)

TABLE 28 HIFU – SONABLATE VS AMBLATHERM (SAFETY FEATURE)

TABLE 29 PREFERECE OF TREATMENT – SURGERY VS RADIATION THERAPY

TABLE 30 PROCESS OF TREATMENT – SURGERY VS RADIATION THERAPY

TABLE 31 BENEFITS OF TREATMENT– SURGERY VS RADIATION THERAPY

TABLE 32 SIDE-EFFECTS AND DRAWBACKS OF TREATMENT– SURGERY VS RADIATION THERAPY

TABLE 33 AVERAGE PRICING OF DEVICES

TABLE 34 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2019–2024)

TABLE 35 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2025–2030)

TABLE 36 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 37 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2025–2030)

TABLE 38 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2019–2024)

TABLE 39 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2025–2030)

TABLE 40 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2019–2024)

TABLE 41 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2025–2030)

TABLE 42 SONACARE MEDICAL LLC – AT A GLANCE

TABLE 43 EDAP TMS SA – AT A GLANCE

TABLE 44 EDAP TMS SA – KEY FINANCIAL SUMMARY

TABLE 45 PROFOUND MEDICAL CORPORATION – AT A GLANCE

TABLE 46 PROFOUND MEDICAL CORPORATION – KEY FINANCIAL SUMMARY

TABLE 47 ECKERT & ZIEGLER AG – AT A GLANCE

TABLE 48 ECKERT & ZIEGLER AG – KEY FINANCIAL SUMMARY

TABLE 49 HEALTHTRONICS INC. – AT A GLANCE

TABLE 50 BOSTON SCIENTIFIC CORPORATION – AT A GLANCE

TABLE 51 BOSTON SCIENTIFIC CORPORATION – KEY FINANCIAL SUMMARY

TABLE 52 ELEKTA AB – AT A GLANCE

TABLE 53 ELEKTA AB – KEY FINANCIAL SUMMARY

TABLE 54 ACCURAY INCORPORATED – AT A GLANCE

TABLE 55 ACCURAY INCORPORATED – KEY FINANCIAL SUMMARY

TABLE 56 VARIAN MEDICAL SYSTEMS INC. – AT A GLANCE

TABLE 57 VARIAN MEDICAL SYSTEMS INC. – KEY FINANCIAL SUMMARY

TABLE 58 BECTON, DICKINSON AND COMPANY – AT A GLANCE

TABLE 59 BECTON, DICKINSON AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 60 INTUITIVE SURGICAL INC. – AT A GLANCE

TABLE 61 INTUITIVE SURGICAL INC. – KEY FINANCIAL SUMMARY

TABLE 62 VIEWRAY INC. – AT A GLANCE

TABLE 63 VIEWRAY INC. – KEY FINANCIAL SUMMARY

TABLE 64 PROVISION HEALTHCARE – AT A GLANCE

TABLE 65 ISORAY INC. – AT A GLANCE

TABLE 66 ISORAY INC. – KEY FINANCIAL SUMMARY

TABLE 67 THERAGENICS CORPORATION – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 4 SPLIT OF PRIMARY INFORMATION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 7 SPLIT OF PRIMARY RESEARCH BY COMPANY AND DESIGNATION

FIG 8 DATA TRIANGULATION APPROACH

FIG 9 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET SUMMARY

FIG 10 BARGAINING POWER OF BUYERS

FIG 11 BARGAINING POWER OF SUPPLIERS

FIG 12 INTENSITY OF RIVALRY

FIG 13 THREAT OF NEW ENTRANTS

FIG 14 THREAT OF SUBSTITUTES

FIG 15 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET SNAPSHOT

FIG 16 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, SHARE & $M (2023)

FIG 17 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2019–2030)

FIG 18 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2019–2030)

FIG 19 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2019–2030)

FIG 20 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2019–2030)

FIG 21 PRODUCT BENCHMARKING OF KEY PLAYERS

FIG 22 EDAP TMS SA – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2023)

FIG 23 PROFOUND MEDICAL CORPORATION – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 24 ECKERT & ZIEGLER AG – REVENUE SPLIT BY SEGMENT AND BY GEOGRAPHY (2023)

FIG 25 BOSTON SCIENTIFIC CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 26 ELEKTA AB – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 27 ACCURAY INCOPORATED – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 28 VARIAN MEDICAL SYSTEMS INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 29 BECTON, DICKINSON AND COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 30 INTUITIVE SURGICAL INC. – REVENUE SPLIT PRODUCT AND SERVICE AND GEOGRAPHY (2023)

FIG 31 VIEWRAY INC. – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 32 ISORAY INC. – REVENUE SPLIT BY GEOGRAPHY (2023)